FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W210546961> ?p ?o ?g. }

• W210546961 abstract "Objectives To conduct a systematic review and meta-analysis assessing the prognostic value and test performance (analytic validity, clinical validity, clinical utility, and harms) associated with 11 prognostic molecular pathology tests. Many of these tests are indicated for prediction of therapeutic responses, but this review focuses on their potential use as prognostic factors. Our overarching question was whether there is direct evidence that the addition of these molecular pathology tests changed physician decision making and improved outcomes for adult patients. We evaluated the following tests: microsatellite instability assessment by polymerase chain reaction (PCR) for colorectal cancer (CRC), MLH1 promoter methylation for CRC, KRAS mutation testing for CRC, BRAF mutation testing for CRC, Oncotype DX Colon mRNA expression for CRC, Oncotype DX Breast mRNA expression for breast cancer, MammaPrint mRNA expression for breast cancer, ALK cytogenetics for lung cancer, EGFR mutation testing for lung cancer, KRAS mutation testing for lung cancer, and UroVysion cytogenetics for urinary bladder cancer. Data Sources PubMed®, the Cochrane Library, and EMBASE® (through November 2013); reference lists of pertinent review articles and included studies, test developers’ Web sites, ClinicalTrials.gov, the Food and Drug Administration (FDA) Web site, Health Services Research Projects in Progress, the European Union Clinical Trials Register, the College of American Pathologists (CAP), and data submitted by companies that developed the tests. Review Methods Two investigators independently selected, extracted data from, and rated risk of bias of each study. For clinical validity, we conducted meta-analyses to estimate weighted summary hazard ratios when three or more studies reported an eligible outcome. For the other review questions, we did not find sufficient data to conduct meta-analyses. Therefore, we synthesized the information qualitatively. We graded strength of evidence based on established guidance. Results Evidence from multiple studies supports associations between test results and prognosis, with added value beyond known independent prognostic factors, for MammaPrint, Oncotype DX Breast, KRAS mutation testing for lung cancer, BRAF and KRAS mutation testing for CRC, and microsatellite instability for CRC for at least one of our included outcomes (i.e., risk of recurrence, cancer-specific survival, or overall survival). Although UroVysion is marketed as a diagnostic rather than a prognostic test, limited evidence from two small studies (total N=168) rated as low or medium risk of bias supported associations between test result and prognosis for risk of recurrence. We found no studies that directly assessed the impact of a test of interest on both physician decision-making and downstream health outcomes to establish clinical utility. We attempted to construct an indirect chain of evidence to answer the overarching question, but we were unable to do so. Even in the cases where the tests seemed to add value in determining prognosis (i.e., evidence of clinical validity), we found no evidence that using the test was related to improved outcomes for patients. However, for impact of test use on treatment decisions, we found moderate strength of evidence that Oncotype DX Breast leads to changes in treatment decisions. Although the decision changes were observed in both directions for individual patients, studies consistently showed an overall shift to less-intensive treatment recommendations as a result of using Oncotype DX Breast, with fewer recommendations for chemotherapy (and less exposure to potential harms of chemotherapy). Limitations We were not able to directly address the prognostic value of these tests for the Medicare population. There were several studies that included patients from the Medicare age group and although the impact of these tests were not analyzed with specific reference to this population, we did not come across any evidence that suggested that the prognostic value of these tests would be different for the Medicare population. Conclusions Modest evidence supports added prognostic value (i.e., clinical validity) for over half of the tests evaluated, and that Oncotype DX Breast leads to changes in treatment decisions, but we found no evidence to determine whether using the tests to estimate prognosis leads to improved outcomes for patients." @default.
• W210546961 created "2016-06-24" @default.
• W210546961 creator A5004993894 @default.
• W210546961 creator A5015661435 @default.
• W210546961 creator A5022925111 @default.
• W210546961 creator A5024420238 @default.
• W210546961 creator A5044678886 @default.
• W210546961 creator A5044894170 @default.
• W210546961 creator A5046706945 @default.
• W210546961 creator A5048363096 @default.
• W210546961 creator A5052422429 @default.
• W210546961 creator A5066873971 @default.
• W210546961 creator A5068955067 @default.
• W210546961 creator A5076399844 @default.
• W210546961 creator A5086942445 @default.
• W210546961 date "2014-05-29" @default.
• W210546961 modified "2023-09-26" @default.
• W210546961 title "Technology Assessment of Molecular Pathology Testing for the Estimation of Prognosis for Common Cancers" @default.
• W210546961 cites W1551461559 @default.
• W210546961 cites W1965110865 @default.
• W210546961 cites W1965905026 @default.
• W210546961 cites W1971427051 @default.
• W210546961 cites W1973231330 @default.
• W210546961 cites W1977009999 @default.
• W210546961 cites W1989085620 @default.
• W210546961 cites W1991981766 @default.
• W210546961 cites W2000127060 @default.
• W210546961 cites W2004489444 @default.
• W210546961 cites W2006134385 @default.
• W210546961 cites W2006380677 @default.
• W210546961 cites W2006924771 @default.
• W210546961 cites W2008013090 @default.
• W210546961 cites W2017084683 @default.
• W210546961 cites W2017158584 @default.
• W210546961 cites W2018009295 @default.
• W210546961 cites W2018077845 @default.
• W210546961 cites W2025280540 @default.
• W210546961 cites W2030183705 @default.
• W210546961 cites W2036792965 @default.
• W210546961 cites W2043696829 @default.
• W210546961 cites W2049550983 @default.
• W210546961 cites W2052982012 @default.
• W210546961 cites W2053652750 @default.
• W210546961 cites W2056450557 @default.
• W210546961 cites W2058408106 @default.
• W210546961 cites W2058646321 @default.
• W210546961 cites W2059216255 @default.
• W210546961 cites W2065028684 @default.
• W210546961 cites W2070302508 @default.
• W210546961 cites W2072599380 @default.
• W210546961 cites W2073434270 @default.
• W210546961 cites W2077235816 @default.
• W210546961 cites W2095512478 @default.
• W210546961 cites W2099231097 @default.
• W210546961 cites W2104573387 @default.
• W210546961 cites W2105882193 @default.
• W210546961 cites W2107638293 @default.
• W210546961 cites W2108619730 @default.
• W210546961 cites W2112316706 @default.
• W210546961 cites W2112761899 @default.
• W210546961 cites W2113656973 @default.
• W210546961 cites W2115162082 @default.
• W210546961 cites W2121807915 @default.
• W210546961 cites W2125204079 @default.
• W210546961 cites W2128054670 @default.
• W210546961 cites W2128524311 @default.
• W210546961 cites W2128985829 @default.
• W210546961 cites W2129859749 @default.
• W210546961 cites W2130921932 @default.
• W210546961 cites W2133264822 @default.
• W210546961 cites W2133615432 @default.
• W210546961 cites W2148131511 @default.
• W210546961 cites W2148863957 @default.
• W210546961 cites W2148994354 @default.
• W210546961 cites W2152261578 @default.
• W210546961 cites W2156273110 @default.
• W210546961 cites W2158733632 @default.
• W210546961 cites W2188742179 @default.
• W210546961 cites W2885038346 @default.
• W210546961 cites W3012453300 @default.
• W210546961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25905152" @default.
• W210546961 hasPublicationYear "2014" @default.
• W210546961 type Work @default.
• W210546961 sameAs 210546961 @default.
• W210546961 citedByCount "1" @default.
• W210546961 countsByYear W2105469612014 @default.
• W210546961 crossrefType "book" @default.
• W210546961 hasAuthorship W210546961A5004993894 @default.
• W210546961 hasAuthorship W210546961A5015661435 @default.
• W210546961 hasAuthorship W210546961A5022925111 @default.
• W210546961 hasAuthorship W210546961A5024420238 @default.
• W210546961 hasAuthorship W210546961A5044678886 @default.
• W210546961 hasAuthorship W210546961A5044894170 @default.
• W210546961 hasAuthorship W210546961A5046706945 @default.
• W210546961 hasAuthorship W210546961A5048363096 @default.
• W210546961 hasAuthorship W210546961A5052422429 @default.
• W210546961 hasAuthorship W210546961A5066873971 @default.
• W210546961 hasAuthorship W210546961A5068955067 @default.
• W210546961 hasAuthorship W210546961A5076399844 @default.
• W210546961 hasAuthorship W210546961A5086942445 @default.

• next